CN101052416B - 表达g250的肿瘤的改进的辅助治疗 - Google Patents

表达g250的肿瘤的改进的辅助治疗 Download PDF

Info

Publication number
CN101052416B
CN101052416B CN2005800205034A CN200580020503A CN101052416B CN 101052416 B CN101052416 B CN 101052416B CN 2005800205034 A CN2005800205034 A CN 2005800205034A CN 200580020503 A CN200580020503 A CN 200580020503A CN 101052416 B CN101052416 B CN 101052416B
Authority
CN
China
Prior art keywords
patients
antibody
antigen
use according
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800205034A
Other languages
English (en)
Chinese (zh)
Other versions
CN101052416A (zh
Inventor
O·威尔赫姆
S·瓦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Wilex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex AG filed Critical Wilex AG
Publication of CN101052416A publication Critical patent/CN101052416A/zh
Application granted granted Critical
Publication of CN101052416B publication Critical patent/CN101052416B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2005800205034A 2004-07-02 2005-06-29 表达g250的肿瘤的改进的辅助治疗 Expired - Fee Related CN101052416B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
US60/584,679 2004-07-02
PCT/EP2005/006994 WO2006002889A2 (en) 2004-07-02 2005-06-29 Improved adjuvant therapy of g250-expressing tumors

Publications (2)

Publication Number Publication Date
CN101052416A CN101052416A (zh) 2007-10-10
CN101052416B true CN101052416B (zh) 2013-07-10

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800205034A Expired - Fee Related CN101052416B (zh) 2004-07-02 2005-06-29 表达g250的肿瘤的改进的辅助治疗

Country Status (13)

Country Link
US (1) US7691375B2 (https=)
EP (2) EP1763367A2 (https=)
JP (1) JP2008505143A (https=)
KR (1) KR101205289B1 (https=)
CN (1) CN101052416B (https=)
AU (1) AU2005259481B2 (https=)
BR (1) BRPI0512854A (https=)
CA (1) CA2566950A1 (https=)
DK (1) DK2497497T3 (https=)
ES (1) ES2641089T3 (https=)
MX (1) MXPA06013240A (https=)
RU (2) RU2371198C2 (https=)
WO (1) WO2006002889A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
CN102576025A (zh) 2009-09-18 2012-07-11 三菱化学株式会社 肝细胞癌标记物
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2901531C (en) 2013-02-22 2022-03-29 Wilex Ag Caix stratification based cancer treatment
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
MXPA03006992A (es) * 2001-02-07 2003-11-18 Wilex Ag Linea de celulas hibridoma g250 y su uso para la produccion de anticuerpos monoclonales.
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bleumer I., et al..A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma.《European Urology》.2002,第S1卷(第1期),112. *

Also Published As

Publication number Publication date
WO2006002889A3 (en) 2006-10-05
EP2497497A1 (en) 2012-09-12
RU2371198C2 (ru) 2009-10-27
RU2009122344A (ru) 2010-12-20
DK2497497T3 (en) 2017-08-14
US7691375B2 (en) 2010-04-06
AU2005259481B2 (en) 2010-04-22
EP2497497B1 (en) 2017-06-21
MXPA06013240A (es) 2007-02-28
US20070207157A1 (en) 2007-09-06
KR101205289B1 (ko) 2012-11-27
ES2641089T3 (es) 2017-11-07
CN101052416A (zh) 2007-10-10
RU2519340C2 (ru) 2014-06-10
WO2006002889A2 (en) 2006-01-12
AU2005259481A1 (en) 2006-01-12
JP2008505143A (ja) 2008-02-21
RU2007104040A (ru) 2008-08-10
CA2566950A1 (en) 2006-01-12
BRPI0512854A (pt) 2008-04-08
KR20070036085A (ko) 2007-04-02
EP1763367A2 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
Milette et al. Molecular pathways: targeting the microenvironment of liver metastases
AU2018241099B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
CN110882385B (zh) 抗pd-1抗体在治疗肿瘤中的用途
CN108026173A (zh) 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
US20170327578A1 (en) Anti-ceacam1 recombinant antibodies for cancer therapy
JP2022058699A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
WO2016029073A2 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
KR20170060042A (ko) Alk 억제제의 조합 요법
CN109476753A (zh) 用于治疗肿瘤的方法的抗-pd-1抗体
Denmark et al. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update
CN115066260A (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
CN112292151A (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
JP2020519576A (ja) 肝細胞癌の治療
CN115052628B (zh) 抗pd-1抗体在治疗肿瘤中的用途
CN115052629A (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN115364209A (zh) 抗pd-1抗体联合化疗治疗食管癌的用途
Elnemr et al. Recent Advances and Surgical Applications of Monoclonal Antibodies
Grenader et al. Influence of vascular endothelial growth factor inhibition on simple renal cysts in patients receiving bevacizumab-based chemotherapy
RU2361614C2 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
CN118871463A (zh) 用于治疗癌症的方法和组合物
Plimack et al. Kidney cancer
Van Ooteghem et al. Members of the jury
Kai et al. Clinicopathological Cases: Summaries of Papers
HK1101348B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130710

Termination date: 20190629